Search results
Results from the WOW.Com Content Network
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma. [1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation .
Dihydroxyacetone phosphate (DHAP, also glycerone phosphate in older texts) is the anion with the formula HOCH 2 C(O)CH 2 OPO 3 2-. This anion is involved in many metabolic pathways , including the Calvin cycle in plants and glycolysis .
Glycerol 3-phosphate is synthesized by reducing dihydroxyacetone phosphate (DHAP), an intermediate in glycolysis. The reduction is catalyzed by glycerol-3-phosphate dehydrogenase. DHAP and thus glycerol 3-phosphate can also be synthesized from amino acids and citric acid cycle intermediates via the glyceroneogenesis pathway. + NAD(P)H + H + → ...
DHAP and thus glycerol 1-phosphate is also possible to be synthesized from amino acids and citric acid cycle intermediates via gluconeogenesis pathway. + NAD(P)H + H + → + NAD(P) + Glycerol 1-phosphate is a starting material for de novo synthesis of ether lipids, such as those derived from archaeol and caldarchaeol .
D-glyceraldehyde 3-phosphate is also of some importance since this is how glycerol (as DHAP) enters the glycolytic and gluconeogenic pathways. Furthermore, it is a participant in and a product of the pentose phosphate pathway .
The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS).
This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license.: You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...